Page last updated: 2024-10-26

etodolac and Dermatitis Exfoliativa

etodolac has been researched along with Dermatitis Exfoliativa in 1 studies

Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).
etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Seara, V1
Costa-Fernandes, S1
Duarte, M1
Maia, L1

Other Studies

1 other study available for etodolac and Dermatitis Exfoliativa

ArticleYear
Etodolac-induced erythroderma.
    Dermatology online journal, 2021, Nov-15, Volume: 27, Issue:11

    Topics: Aged; Anti-Infective Agents, Local; Anti-Inflammatory Agents; Betamethasone; Cyclooxygenase 2 Inhibi

2021